NewsAccel-Heal to be available on prescription from October 2015

Accel-Heal to be available on prescription from October 2015


Accel-Heal to be available on prescription from October 2015Synapse Electroceutical Ltd, the company behind Accel-Heal is pleased to confirm that Accel-Heal will be listed in the October 2015 edition of the Drug Tariff, and available on prescription across England & Wales.

Speaking about this development John Gildersleeve, Chief Executive Officer of Synapse said "This is a major milestone for us as a company, and for Accel-Heal as a product. The availability of Accel-Heal on prescription signals a new era for the treatment of complex wounds*, and acceptance of our electroceutical technology as a mainstream treatment."

Dr David Chapman - Jones, Chief Scientific Officer at Synapse added; "Accel-Heal is an externally applied electroceutical (EAE) treatment that targets a key underlying cause of why wounds do not heal and become complex. Current healing rates and clinical outcomes in patients with complex wounds suggests that existing practice for the treatment of Venous Leg Ulcers (VLUs) is inadequate and fiscally burdensome. The application of Accel-Heal can improve VLU healing rates and patient outcomes to provide significant cost savings to health care providers.  Incorporating Accel-Heal into clinical care pathways will ease the resource burden on the NHS and its availability on Drug Tariff will make it more widely available to all patients who need it."

Commenting about Accel-Heal's availability on prescription Professor Peter Vowden, Consultant Vascular Surgeon and Visiting Professor, Bradford Teaching Hospitals NHS Trust, said "I am delighted that this innovative product will now be available on Drug Tariff and will increase the range of treatments available." 

Read more about Accel-Heal